[Effect of agonist anti-CD40 mAb 5C11 on the induction and biological characteristics of leukemic dendritic cells].
OBJECTIVE
To study the impact of an agonist anti-CD(40) monoclonal antibody 5C11 on the induction and biological characteristics of leukemic dendritic cells.


METHODS
Combinations of 5C11 and different cytokines were used to induce differentiation of leukemic blasts into dendritic cells. Morphology was observed by light microscopy. Surface antigens of the induced cells were analyzed by fluorescence-activated cell sorting (FACS), the yields of dendritic cell by cell counting, the levels of IL-6 and IL-12 by ELISA, T cell proliferating activity by allo-mixed lymphocyte reaction (MLR) in vitro. Allogeneic T cells were stimulated with leukemic dendritic cells and T-cell cytotoxicity was measured by MTT assay.


RESULTS
When cultured with combinations of 5C11 and different cytokines, the leukemic cells isolated from the patients could differentiate into dendritic cells. The morphology showed typical features of dendritic cells, which expressed high levels of CD(40), CD(80) and CD(86). In comparison with the original leukemia cells, the leukemic dendritic cells secreted less IL-6 but more IL-12 (P < 0.05). The leukemic dendritic cells were potent to stimulate the proliferation of allogeneic T cells, and the latter was able to lyse the original leukemia cells.


CONCLUSIONS
Leukemic blasts could be induced to differentiate into functional dendritic cells. It may be of great value in the adoptive immunologic therapy of leukemia.
Wang
Zheng-fei
ZF
Biotechnology Institute of Suzhou University, Suzhou 215007, China.
Yu
Ge-hua
GH
Zhu
Zi-ling
ZL
Zhu
Yi-pei
YP
Wang
Feng-ming
FM
Pan
Jian-zhong
JZ
Gu
Zong-jiang
ZJ
Zhang
Xue-guang
XG
D000911:Antibodies, Monoclonal / Q000276:immunology*; D019013:CD40 Antigens / Q000502:physiology*; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D018664:Interleukin-12 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D007938:Leukemia / Q000276:immunology* / Q000473:pathology / Q000628:therapy
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D015850:Interleukin-6; D018664:Interleukin-12